Monte Rosa Therapeutics (GLUE) Equity Average (2023 - 2025)
Monte Rosa Therapeutics' Equity Average history spans 3 years, with the latest figure at $239.4 million for Q4 2025.
- For Q4 2025, Equity Average rose 11.79% year-over-year to $239.4 million; the TTM value through Dec 2025 reached $239.4 million, up 11.79%, while the annual FY2025 figure was $228.0 million, 13.38% up from the prior year.
- Equity Average reached $239.4 million in Q4 2025 per GLUE's latest filing, down from $257.0 million in the prior quarter.
- In the past five years, Equity Average ranged from a high of $271.6 million in Q2 2025 to a low of $165.9 million in Q1 2024.
- Average Equity Average over 3 years is $219.1 million, with a median of $215.1 million recorded in 2024.
- Peak YoY movement for Equity Average: decreased 17.53% in 2024, then surged 50.13% in 2025.
- A 3-year view of Equity Average shows it stood at $181.9 million in 2023, then grew by 17.76% to $214.2 million in 2024, then rose by 11.79% to $239.4 million in 2025.
- Per Business Quant, the three most recent readings for GLUE's Equity Average are $239.4 million (Q4 2025), $257.0 million (Q3 2025), and $271.6 million (Q2 2025).